托尼克斯制药控股公司（Tonix Pharmaceuticals Holding Co，股票代码：TNXP）周五盘后股价大幅上涨19.79%，引发市场广泛关注。这一显著涨幅与公司重大利好消息密切相关。
据报道，美国食品和药物管理局（FDA）已批准托尼克斯制药公司的新药，用于控制与纤维肌痛这一慢性疾病相关的疼痛。这款名为"Tonmya"的非阿片类药物是15年来纤维肌痛患者的首个新治疗选择，将以睡前服用的药片形式改善睡眠质量并缓解疼痛。
托尼克斯制药公司首席执行官塞斯·莱德曼表示，这是首次针对非恢复性睡眠开发的药物，公司认为非恢复性睡眠在纤维肌痛中起着重要作用。分析师预计，该药物在美国市场的销售峰值可能达到8亿美元。公司计划在今年第四季度推出这款新药，这无疑将为公司带来可观的收入增长，也解释了投资者对公司前景的乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.